Boston Scientific Corporation has released its financial results for the third quarter of 2026, highlighting a slight increase in net sales but a decrease in net income. The report, filed on October 28, 2026, indicates that the company generated net sales of $5.138 billion, marking a 1.5% increase compared to the same period last year. However, net income attributable to common stockholders fell to $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, a year earlier.

Mike Mahoney, the chairman and CEO of Boston Scientific, acknowledged the challenges faced by the company, particularly in light of a recent cybersecurity incident. He expressed pride in the resilience and urgency shown by the global teams in restoring operations and supporting customers. "As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio, and strong pipeline of meaningful innovation," Mahoney stated.

Background

Boston Scientific Corporation, incorporated in Delaware, operates in the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company trades on the New York Stock Exchange under the ticker symbol BSX. Recent filings include an 8-K on October 28, 2026, detailing the financial results for the third quarter, along with previous filings throughout October and September.

What the Filing Says

The filing indicates that Boston Scientific's net sales for the third quarter of 2026 were $5.138 billion, with a 1.5% increase on a reported, operational, and organic basis compared to the previous year. The company reported a GAAP net income of $582 million, or $0.40 per share, and an adjusted EPS of $0.73, slightly down from $0.75 a year ago.

Impact

The results may affect various stakeholders, including investors, employees, and customers. Investors may be concerned about the decrease in net income, while employees may feel the impact of the ongoing challenges the company faces, including the cybersecurity incident. Customers rely on Boston Scientific's products and services, which could be influenced by the company's operational adjustments in response to these challenges.

What's Next

The filing does not say what happens next. However, the company is likely to continue focusing on its long-term strategy and addressing the issues raised in the recent quarter.